Crystal Lake, Illinois, July 31, 2025 — AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following second quarter results for the period ended June 30, 2025, as compared to the corresponding period of the last fiscal year.
Second Quarter 2025 Highlights (compared to the prior year quarter)
- Reported sales increased 6% and core sales increased 3%
- Reported net income increased 24% to $112 million and adjusted EBITDA increased 13% from the prior year to $218 million
- Reported earnings per share increased 25% to $1.67 and adjusted earnings per share increased 18% to $1.66
- Achieved an adjusted EBITDA margin of 22.6% an increase of 140 basis points
- Returned $100 million to shareholders through share repurchases and dividends
Six Months Year-to-Date 2025 Highlights (compared to the prior year period)
- Reported and core sales grew 2%
- Reported net income increased 10% to $191 million and adjusted EBITDA increased 8% to $402 million
- Reported earnings per share increased 10% to $2.83 and adjusted earnings per share increased 8% to $2.86
- Returned $210 million to shareholders through share repurchases and dividends
“Each of our segments contributed positively to our second quarter results and each expanded their adjusted EBITDA margins. Our Pharma and Closures segments drove the growth through increased volumes and sales of higher value products. We also returned $100 million to shareholders through dividends and share repurchases in the quarter, bringing the total to $210 million in the first half of the year,” said Stephan B. Tanda, Aptar President and CEO.
